Autolus

Nasdaq: AUTL



AUTO1 and AUTO3 Data Update - ASH 2020

December 2020

Disclaimer

These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the "safe harbor" provisions of The Private Securities Litigation Reform Act of 1995, including statements about the safety, therapeutic potential and commercial opportunity of AUTO1 and AUTO3 and the future clinical development of AUTO1 and AUTO3 including progress, expectations as to the reporting of data, conduct and timing; the Company's plans to develop and commercialize its other product candidates and next generation programs including statements regarding the timing of initiation, completion of enrollment and availability of data from the Company's current preclinical studies and clinical trials; the Company's commercialization, marketing and manufacturing capabilities and strategy; and the impact of the ongoing COVID-19 pandemic on the Company's operations and clinical trials. All statements other than statements of historical fact contained in this presentation, including statements regarding the Company's future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risks described in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019, as amended, as well as those set forth from time to time in the Company's subsequent SEC filings, available at www.sec.gov. All information contained herein is as of the date of the presentation, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing the Company's views as of any date subsequent to the date of this presentation.

Certain data in this presentation was obtained from various external sources. Such data speak only as of the date referenced in this presentation and neither the Company nor its affiliates, advisors or representatives make any representation as to the accuracy or completeness of that data or undertake to update such data after the date of this presentation. Such data involve risks and uncertainties and are subject to change based on various factors.

Agenda

1. Welcome and Introduction: Dr. Christian Itin, Chairman and CEO
2. AUTO3 Data Review: Dr. Robert Chen, Executive Director, AUTO3 Program Lead
3. Commercial Opportunity in DLBCL : Brent Rice, Vice President, Chief Commercial Officer
4. AUTO1 Data Review: Dr. Nushmia Khokhar, Head of Clinical Development
5. Commercial Opportunity in Adult ALL: Brent Rice, Vice President, Chief Commercial Officer
6. Summary: Dr. Christian Itin, Chairman and CEO
7. Q&A: Dr. Christian Itin, Dr. Martin Pule (CSO), Andrew Oakley (CFO), Dr. Nushmia Khokhar, Dr. Robert Chen, Brent Rice

Welcome and introduction

Dr. Christian Itin

Chairman and CEO

Broad expertise in CAR T therapy development and market access

Dr. Christian Itin
Chairman & CEO
Previously CEO of Micromet; led development of Blincyto®, the first FDA-approved redirected T cell therapy

Dr. Nushmia Khokhar
SVP, Head of Clinical Development
Board certified oncologist, lead several successful registration trials within industry including global daratumumab program at Janssen Oncology

Dr. Martin Pule
Founder & SVP, CSO
Founder of Autolus; World leading expert in the development of CAR T cell therapies; Clinical senior lecturer & hon. consultant at UCL; Fulbright at Baylor

Dr. Robert Chen
Executive Director, Clinical Development
Previously Associate Professor at City of Hope Medical Center and Associate Director of the Toni Stephenson Lymphoma Center. Authored 100+ peer reviewed publications and abstracts

Andrew Oakley
CFO
17+ years experience as public company CFO in bio-pharma sector; more than 10 years at Actelion

Brent Rice
VP, Chief Commercial Officer
25 years biotech/pharma experience; previously at Juno Therapeutics; 18 years at Amgen

AUTO3 Continues to Show Differentiated Product Profile

Data cut-off date October 30, 2020

- Safety data supports feasibility of outpatient administration
  - AUTO3 was observed to be well tolerated, with low rates of cytokine release syndrome (CRS) and neurotoxicity (NT) reported
  - No prophylactic measures of any kind have been used to manage patients in this study
  - Manageability in the outpatient cohort appears promising

- High complete response rates
  - CR rate was 55% for patients receiving ≥ 150 x 10^6 cells and pre-conditioning with pembrolizumab at Day -1
  - Subsequent analysis indicates that at a dose of 450 x 10^6 cells, CRR is 73%
  - 73% patients reaching a CR, across all cohorts, were without disease progression (median follow up 4 mths)
  - None of the five patients who achieved a CR in the cohort receiving three doses of pembrolizumab had disease progression

- We expect to update on next steps for AUTO3 in Q1 2021

AUTO1 has Potential for Transformational Outcomes in Adult ALL

Data cut-off date November 12, 2020

- High level of sustained CRs, achieved without subsequent stem cell transplant
- Durability of remissions highly encouraging
  - Across all treated patients, event free survival (EFS) at six and 12 months is 69% and 52%, respectively
- AUTO1 remains well tolerated, despite patients having high disease burden and being heavily pre-treated
  - No patients experienced ≥ Grade 3 cytokine release syndrome (CRS) as of data cut-off date
- Phase 1b/2 potential pivotal study underway, expect full data in 2022
  - Escalating COVID-19 pandemic is continuing to impact study conduct
- Adult ALL represents a sizeable market opportunity which requires limited commercial footprint

Data Review

Dr. Robert Chen

Executive Director, AUTO3 Program Lead

Phase 1/2 study of AUTO3, the first bicistronic chimeric antigen receptor (CAR) targeting CD19 and CD22, followed by an anti-PD1 in patients with relapsed/refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Safety Cohorts of the ALEXANDER study*

Autolus

* American Society of Hematology – December 2020

Improving CAR T Cell Immunotherapy In DLBCL

Dual targeting CAR & prevention of CAR T cell inhibition

- CD19 CARs are active in r/r DLBCL
- However unmet need remains with CD19 CAR T cell therapy
  - 29-37% durable CRR in DLBCL[1,2]
  - The potential causes for relapse include:
    - PD-L1 upregulation[3] which contributes to CAR T exhaustion
    - CD19 antigen loss[4]
  - Rate of severe (grade ≥3) cytokine release syndrome (CRS 13-22%) and neurotoxicity (NT 12-28%)[2,4]
- Simultaneous targeting of CD19 and CD22 may reduce the probability of relapse due to antigen loss
- PD1/PDL1 mediated CAR T cell inhibition may be prevented by adding pembrolizumab to the preconditioning regimen



[1] Locke F et al Lancet Oncol 2019
[2] Schuster S et al NEJM 2019
[3] Neelapu S et al ASCO 2018
[4] Neelapu S et al NEJM 2017

AUTO3: First CD19 and CD22 Targeting Bicistronic CAR

Gamma Retroviral-Based Vector with RD114 Pseudotype

- Dual antigen targeting
- Two independent CARs delivered in single retroviral vector
- Humanized binders
- CD22 CAR with novel pentameric spacer
- OX40/41BB costimulatory domains designed to improve persistence
- Independently target CD19 and CD22



Alexander Study Design

AUTO3-DB1, single-arm, open-label, multi-center, Phase 1/2 study



Preconditioning: Flu/Cy

Flu/Cy + Pembro day 14 x 3 doses

Flu/Cy + Pembro day - 1 x 1 dose

Autolus

Phase 1 Outpatient Expansion Cohort

Inclusion / Exclusion

- Subjects who do not have caregiver support (in line with institutional outpatient transplant guidelines) for outpatient/ambulatory care setting
- Subjects who are staying greater than 60 minutes (or whatever is permissible per institutional outpatient transplant guidelines) from the clinical trial site at the time of treatment

Monitoring

- Monitored for at least 10 days in an outpatient/ambulatory care setting
- During the 10 days following AUTO3 infusion, monitored at a minimum every 2 to 3 days. Recommended for the patient to have a daily verbal communication with qualified nurse/medical personnel (phone call)

Autolus

Baseline Patient Characteristics: All Patients

Baseline Patient Characteristics		N=49
Age, median (min-max)		59 (27-83)
Gender, n	Male, Female	29, 20
Current Histology, n	DLBCL NOS tDLBCL High Grade B Cell Lymphoma Primary Mediastinal Large B Cell Lymphoma	34 (69%) 11 (22%) 3 (6%) 1 (2%)
Molecular Risk, n (%)	High Risk - Triple HIT - Double HIT - Double Expressor No High Risk Unknown/Not Done	27 (55%) -5 -14 - 8 13 (27%) 9 (18%)
Disease Stage, n (%)	II III IV	4 (8%) 10 (20%) 35 (71%)
Relapsed/Refractory, n (%)	Refractory Relapsed Relapsed and Refractory	11 (22%) 14 (29%) 24 (49%)
No. Prior Therapies, median (min-max)		3 (1-11)
Prior ASCT, n (%)		15 (31%)
SPD, median (min-max)		18.5 cm (2.1 – 260.8)

Autolus

Treatment Emergent Adverse Events ≥ 25% and SAE ≥ 5%

AEs (Total N = 49)	All Grades n (%)	≥ Grades 3 n (%)
Neutropenia	29 (59%)	28 (57%)
Anaemia	25 (51%)	20 (41%)
Thrombocytopenia	23 (47%)	18 (37%)
Cytokine release syndrome	17 (35%)	1 (2%)
Fever	13 (27%)	0
Infections	13 (27%)	8 (16%)

SAEs (Total N = 49)	All Grades n (%)	≥ Grades 3 n (%)
Cytokine release syndrome	6 (12%)	1 (2%)
Fever	5 (10%)	0
Infections	4 (8%)	4 (8%)
Febrile neutropenia	3 (6%)	3 (6%)

- Majority of ≥ Grade 3 AEs are haematological
- Two patients had death possibly related to AUTO3. One in the setting of disease progression and multiorgan failure and other due to infection in a patient with secondary HLH

Safety by Cohort

	50 x10^6 AUTO3 no pem (N=4)	50 x10^6 AUTO3 D14 pem (N=3)	150-450 x10^6 AUTO3 D14 pem (N=8)	150-450 x10^6 AUTO3 D-1 pem Inpt (N=17)	150-450 x10^6 AUTO3 D-1 pem Outpt (N=17)	Total (N=49)
Safety						
CRS All Grades	1	0	4	5	7	17 (35%)
CRS ≥ Grade 3	0	0*	0	0	1	1 (2%)
NTX All Grades	1	0	0	1	1	3 (6%)
NTX ≥ Grade 3	1	0	0	0	1	2 (4%)

* 1 patient who had no CRS with primary infusion, developed G3 CRS (severe hypoxia) with re-treatment 1 year later which happened in a setting of no CAR T expansion and significant disease burden in lung that had been treated with radiation

CRS grading as ASCT/ASBMT (Lee et al 2019)
Data Cut-off Date: 30-Oct-2020

Cytokine Release Syndrome (CRS)

Low rates of CRS

	Total (N=49)	50×10^6 AUTO3 (N=7)	150×10^6 AUTO3 (N=16)	300×10^6 AUTO3 (N=10)	450×10^6 AUTO3 (N=16)
All Grades	17 (35%)	1 (14%)	4 (25%)	2 (20%)	10 (63%)
Grade 1	10 (20%)	1 (14%)	2 (13%)	2 (20%)	5 (31%)
Grade 2	6 (12%)	0	1 (6%)	0	5 (31%)
≥ Grade 3	1 (2%)	0*	1 (6%)	0	0

* 1 patient who had no CRS with primary infusion, developed G3 CRS (severe hypoxia) with re-treatment 1 year later which happened in a setting of no CAR T expansion and significant disease burden in lung that had been treated with radiation

- No prophylactic measures of any kind
- Median time to CRS 2 days (1-36), Median duration 3 days (1-19)
- Eight patients received tocilizumab (16%)
- No patients received steroids

Autolus

CRS grading as ASCT/ASBMT (Lee et al 2019)
Data Cut-off Date: 30-Oct-2020

Neurotoxicity (NT/ICANS)

Low rates of NT

	Total (N=49)	50×10^6 AUTO3 (N=7)	150×10^6 AUTO3 (N=16)	300×10^6 AUTO3 (N=10)	450×10^6 AUTO3 (N=16)
All Grades	3 (6%)	1 (14%)	2 (13%)	0	0
≥ Grade 3	2 (4%)	1 (14%)	1 (6%)	0	0

- No prophylactic measures of any kind
- No NT of any grade in patients that achieved CR
- All NT atypical in context of tumor progression with zero to minimal CAR T expansion in peripheral blood
  - **1st case of NT (G3):** Day 53. Duration 5 days (G2). The same symptoms of facial/muscle weakness occurred > 10 years ago without specific diagnosis. Resolved.
  - **2nd case of NT (G2):** Day 21. Duration 6 days. AMS* associated with sepsis and narcotic. Resolved.
  - **3rd case of NT (G4):** Day 10. Encephalopathy associated with sepsis, hyponatremia, metabolic acidosis, and multiorgan failure. Patient died of disease progression and multiorgan failure

Autolus

* Altered Mental Status
Data Cut-off Date: 30-Oct-2020

Efficacy Data by Cohort

	50 $x10^6$ AUTO3 no pem (N=4)	50 $x10^6$ AUTO3 D14 pem (N=3)	150-450 $x10^6$ AUTO3 D14 pem (N=8)	150-450 $x10^6$ AUTO3 D-1 pem Inpt (N=17)	150-450 $x10^6$ AUTO3 D-1 pem Outpt (N=17)	Total (N=49)
N Evaluable*	4	2	8	15	14	43
ORR (CR+PR)	2 (50%)	2 (100%)	5 (63%)	10 (67%)	9 (64%)	28 (65%)
CR	1 (25%)	1 (50%)	4 (50%)	9 (60%)	7 (50%)	22 (51%)
PR	1 (25%)	1 (50%)	1 (13%)	1 (7%)	2 (14%)	6 (14%)

- 150-450 x 10^6, Day -1 pem (N=29 evaluable): ORR 66%, CRR 55%

- Evaluable = PET positive disease prior to start of pre-conditioning and infused at least 28 days prior to data Cut-off date
- Response evaluation per Lugano 2014 criteria

ORR = Overall response rate; CR = Complete response; PR = Partial response; PD = Progressive disease

Efficacy Data - Best Overall Responses

Complete responses observed at all doses

	Total (N=49)	50×10^6 AUTO3 (N=7)	150×10^6 AUTO3 (N=16)	300×10^6 AUTO3 (N=10)	450×10^6 AUTO3 (N=16)
N Evaluable*	43	6	13	9	15
ORR	28 (65%)	4 (67%)	4 (31%)	7 (78%)	13 (87%)
CR	22 (51%)	2 (33%)	4 (31%)	5 (56%)	11 (73%)
PR	6 (14%)	2 (33%)	0	2 (22%)	2 (13%)

- Across all doses CRR of 51% (n=43)
- Doses ≥ 300×10^6, CRR of 62% (n=26)
- Doses ≥ 450×10^6, CRR of 73% (n=15)

Autolus

*Evaluable = PET positive disease prior to start of pre-conditioning and infused at least 28 days prior to data Cut-off date
Data Cut-off Date: 30-Oct-2020

Disease Assessment of CR Patients

16/22 (73%) without progression, median follow up of 4 months



Autolus

Data Cut-off Date: 30-Oct-2020

Cellular Kinetics by Best Overall Response

CR/PR are associated with higher expansion and longer persistence



	CR/PR (N=28)	SD/PD (N=13)
Tmax (days) median (range)	11 (7 – 35)	12 (7 – 28)
Cmax (copies/µg) Geo-mean (CV%)	6129 (175)	1841 (722)
AUC0-28 (copies/µg day) Geo-mean (CV%)	54419 (199)	13731 (1275)

- Ongoing CAR T persistency observed at ≥ 18 months

Evaluable = PET positive disease prior to start of pre-conditioning, infused at least 28 days prior to data Cut-off date and with at least one sample providing evaluable cellular kinetic data

Data Cut-off Date: 30-Oct-2020

Autolus

AUTO3 Healthcare Utilizations in Outpatient Cohort

Outpatient infusion of AUTO3 is feasible

	150-450 x10^6 AUTO3 D-1 pem Outpt (N=17)
AUTO3 infusion inpatient	4
AUTO3 infusion outpatient	13
Admission post AUTO3	5 (38%)
ICU admission	0

- 5 patients received AUTO3 outpatient but admitted (due to FN and CRS)
- Median duration of hospitalisation was 5 days (range 1-9 days)

Conclusions

Phase I Cohorts, ALEXANDER study

- AUTO3 has a tolerable and best-in-class safety profile:
  - — 35% CRS (2% ≥ Grade 3 CRS) with primary infusion
  - — 6% NT/ICANs* (4% ≥ Grade 3 NT/ICANs)
    - Patients that achieved CRs, where robust expansion was observed, no severe NT of any grade was seen
    - All three cases of NT in setting of disease progression, very minimal / undetectable CAR-T cells in peripheral blood and with confounding factors
- AUTO3 shows high rate of complete responses
  - — Overall CRR of 51% (N=43)
  - — Among patients receiving 450 x 10^6 AUTO3, CRR of 73% (N=15)
  - — Ongoing CR observed beyond 24 months
- Outpatient administration is feasible with low admission rate (38%)

Autolus

* Immune effector cell-associated neurotoxicity syndrome
Data Cut-off Date: 30-Oct-2020

Commercial Opportunity – DLBCL

Brent Rice

Vice President, Chief Commercial Officer, US

Outpatient Cohort Reinforces AUTO3 Feasibility in Outpatient Setting

AUTO3 has the potential to be a true outpatient therapy



Source: US Retrospective Claims Analysis by Site of Distribution
*Autolus approximate estimates

Approved CD19 CAR T Products

- Patients receive approved products as inpatients in CoEs because of the high rate & severity of toxicities plus intensity of patient management
- Market opportunity limited to ~20% of patients

AUTO3

- Minimal toxicity management should allow treatment across all settings of care
- AUTO3 potentially grows the addressable market and maximizes reimbursement options compared to approved products
- >80% of 3L+ and 2L DLBCL patients treated outside of Academic CoEs

DLBCL: Approved CAR T's are Unable to Penetrate Outpatient Setting

Creates significant opportunity for AUTO3 with potential to go where patients reside

Percentage of patients who currently receive a CAR T in outpatient or inpatient setting



- 97% of patients receive approved CAR Ts as inpatients in CoEs because of
  - the high rate and severity of toxicities and
  - the need for intensive patient management
- In the Outreach study*, 63% of patients treated with liso-cel in an outpatient setting required hospitalization
- AUTO3 is designed to have best-in-class safety profile potentially best suited for outpatient use

Autolus

Source: Komodo Health, ASCO 2020: 8037
* Initial results from the Outreach Study, ASH 2020
** Neurological Events

AUTO3 Continues to Deliver on Promise for Patients in Outpatient Setting

Differentiated product profile has potential for access to full market opportunity

- Across all lines of DLBCL the vast majority of patients are treated outside of COEs
- Going where patients are treated could eliminate the challenges involved in establishing referral networks
- Clinical profile and potential for flexible reimbursement has AUTO3 poised to penetrate outpatient setting
- AUTO3 positioned to fully reach addressable 2L and 3L+ patient opportunity

Data Review

Dr. Nushmia Khokhar
Head of Clinical Development

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Adult Relapsed/Refractory B-Acute Lymphoblastic Leukaemia*

* American Society of Hematology – December 2020

Adult B-Acute Lymphoblastic Leukemia:

Current standard of care

- Adult B-ALL prognosis is poor; long-term remission rates limited to 30-40%
  - 50% of all adult patients will relapse, with 5-year OS 7% (Fielding et al., 2007)
- Currently the only curative option for r/r ALL is allo-SCT in CR2, but <50% achieve CR2
- Blinatumomab and inotuzumab ozogamicin act as a bridge to allo-SCT (Topp et al. 2015; Kantarjian et al., 2019)
- CD19 CAR T can deliver excellent response rates but with considerable toxicity, particularly in elderly patients

Currently available CARs: *high affinity CD19 binders*

AUTO1: *Lower affinity CD19 binder with fast off-rate**

- Physiological T-cell activation
- Reduced toxicity
- Improved engraftment
- Potential long-term persistence, to deliver sustained responses

Autolus

*Ghorashian S, Pule MA, Amrolia P et al. *Nature Medicine* 2019.

ALLCAR19 Study Design

B-ALL arm



BM blasts ≤20% **Day 0 Infuse 100 x 10^6 CD19 CAR T-cells** **Day 9 Infuse 310 x 10^6 CD19 CAR T-cells**

BM blasts >20% **Day 0 Infuse 10 x 10^6 CD19 CAR T-cells** **Day 9 Infuse 400 x 10^6 CD19 CAR T-cells**

No G3-5 CRS/ICANS

Autolus

ALLCAR19 (NCT02935257)

ALLCAR19 Study:

Endpoints and eligibility

Primary Endpoints

- Grade 3-5 toxicity causally related to the ATIMP
- Feasibility of adequate leucapheresis & generation of AUTO1 CAR T-cells

Inclusion

- Age 16 to 65 years
- High risk or relapsed histologically confirmed CD19+ B-ALL following standard therapy requiring salvage in whom alternative therapies are deemed inappropriate by their treating physician

Secondary Endpoints

- Depth of response at 1 and 3 months post ATIMP
- Persistence of CD19CAR T-cells in peripheral blood
- Incidence and duration of hypogammaglobulinaemia & B-cell aplasia
- Relapse rate, disease-free, overall survival, 1 & 2 years

Exclusion

- CD19 negative disease
- Overt CNS involvement/isolated extramedullary disease
- Active hepatitis B, C or HIV infection
- Stem Cell Transplant patients only: no active GVHD
- Significant neurotoxicity following blinatumomab

No exclusion for prior blinatumomab or inotuzumab ozogamicin

ALLCAR19 Manufacturing:
Product characteristics & feasibility



- 100% of successful harvests result in a QP released product
- Semi-automated closed manufacturing process was used in 18/24 products
- Advantages of closed process includes:
  - rapid, standardised manufacture
  - trend towards lower exhaustion markers
  - enrichment for Tcm and Tnaive CAR+ cells (47%)
- Mean transduction efficiency 66.5%
  - Range 50-83%



Autolus

Patient Characteristics:

Treated (n=20)

Baseline Characteristics	N=20 (%)
Median age, years (range)	43 (18-62)
Gender	13M/7F
Chromosomal/Molecular status	
• Ph+ (bcr-abl)	6 (30%)
• MLL	1 (5%)
• Other	8 (40%)
• Normal	4 (20%)
• Failed	1 (5%)
Prior lines of treatment	
• Median (range)	3 (2-6)
• **Prior Inotuzumab**	**10 (50%)**
• **Prior Blinatumomab**	**5 (25%)**
• **Prior allo-HSCT**	**13 (65%)**
- sibling/haplo/VUD	4p/1p/8p

Leukemia Burden Prior to Lymphodepletion	N=20 (%)
Morphological disease	
• ≤ 5% blasts	7 (35%)
• 5 - 49% blasts	4 (20%)
• **≥ 50% blasts**	**9 (45%)**
CNS status at registration	
• CNS 1	0 (0%)
• CNS II – III	0 (0%)
Other extranodal sites	3 (16%)

Autolus

20 patients have been infused (data cut off 12-Nov-2020)

AUTO1 Pharmacokinetics:

Expansion and persistence by qPCR



ALLCAR19 qPCR PK all patients (n = 19)		*Mueller 2017 (responders)
AUC DO-28 (Geometric Mean) (Copies/µg x days)	**750 320**	**342 732**
Half life (Median Days)	17 (Range 11-29)	14.2
Max CART T Level (Geometric Mean) (Copies/µg)	117 670	47 988
T (Cmax) (Median Days)	14 (Range 7-21)	

Autolus

* Mueller, KT et. al. Blood 130(21) 2017

Safety Profile

CRS (Lee Criteria)	Neurotoxicity (ICANS#)	≥ Grade 3 Cytopenia	Day -6	At Day 28
• CRS (any) in 10/20 • Grade 2 in 7/20 • ≥ Grade 3 CRS in 0/20	• ICANS (any) in 4/20 • Grade 2 in 1/20 • Grade 3 in 3/20	• ≥ Grade 3 Neutropenia	7/20	8/17

- CRS
  - All patients who developed Grade 2 CRS had high burden B-ALL
  - Tocilizumab was used in 7/20 patients (35%)
- Neurotoxicity (ICANS)
  - ≥ Grade 2 ICANS was reported in 4/20 patients: all had ≥ 50% blasts; all cases were preceded by CRS
  - 3/4 cases resolved to G1 in <24h with steroids, 1/4 cases resolved to G1 in 72h with steroids
- ≥ Grade 3 neutropenia:
  - Pre-dated treatment in 7/20 patients
  - At Day 28, 8/17 evaluable patients had ≥ Grade 3 neutropenia with most resolving by Month 2/3
- 7/20 patients died on study:
  - 2/20 died from progressive B-ALL
  - 1/20 died post-progression from allo-transplant-related complications (VOD/sepsis)
  - 4/20 from infection: 2/4 before D28 (sepsis; invasive fungal); 1/4 at M6 in CR (MDR-pseudomonas in blood); 1/4 at M3 of COVID-19

Autolus

 # Immune Effector Cell Associated Neurotoxicity Syndrome
CRS & NT will be graded using the ASTCT/ASBMT Consensus Grading (Lee et al. 2019)

Efficacy & Duration



MRD < 10^{-4} by PCR or < 5 x 10^{-4} based on limits of detection of assay
Data Cut-off 12-Nov-2020, Evaluable = All patients with at least M1 follow-up or death prior to Month 1

Autolus

AUTO1: Efficacy Overview



		All patients Est [95% CI]	Closed process Est [95% CI]
	N *	19	13
	ORR	84%	92%
	MRD Neg CR	84%	92%
DOR			
	Median	Not reached	Not reached
	6 months	81% [52%, 94%]	83% [48%, 96%]
	12 months	68% [39%, 85%]	65% [31%, 85%]
EFS			
	Median	Not reached	Not reached
	6 months	69% [43%, 85%]	85% [52%, 96%]
	12 months	52% [28%, 71%]	60% [29%, 81%]
OS			
	Median	Not reached	Not reached
	6 months	68% [43%, 84%]	85% [51%, 96%]
	12 months	63% [37%, 80%]	76% [43%, 92%]

N = All patients with at least M1 follow-up or RIP prior to Month 1.
Event = death or morphological relapse.
DOR, EFS and OS data are preliminary considering the small n

ALLCAR19 Study:

Extending eligibility to Indolent NHL, HG-NHL and CLL

Cohort 1: Indolent B-NHL
(Dose = 200 million CD19 CAR T-cells)

- relapsed/refractory (r/r) Follicular Lymphoma
- r/r Mantle Cell Lymphoma
- r/r Marginal Zone Lymphoma
- ≥2 prior lines of therapy including Rituximab and anthracycline

Cohort 2: High grade B-NHL
(Dose = 200 million CD19 CAR T-cells + Pembrolizumab)

- r/r DLBCL, PMBCL, transformed FL
- not Richter's transformation
- ≥2 prior lines of therapy including Rituximab and anthracycline

Cohort 3: CLL/SLL
(Dose = 230 million CD19 CAR T-cells/ split dose)

- r/r CLL/SLL
- ≥2 prior lines of therapy including Ibrutinib/BTKi

ALLCAR19 Study:

Cohort 1:Indolent NHL- products and demographics





- N=6 products QP released
- Semi-automated, closed manufacturing
- Tcm/Tnaive CAR+ (36%)
- Transduction efficiency (mean 76%)

Baseline Characteristics	N=8 (%)
Median age, years (range)	57 (39 - 68)
Gender	6M/2F
Histological diagnoses • MCL • FL	 2 (25%) 6 (75%)
Disease Stage • Stage I/II • Stage III/IV	 0 (0) 8 (100%)
Prior lines of treatment • Median (range) • Prior ASCT • Prior allo-HSCT - sibling/haplo/VUD	 3 (2-4) 4 (50%) 1 (12.5%) 0p/0p/1p

Autolus

4 patients have been infused (data cut off 12-Nov-2020)

ALLCAR19 Study:

Cohort 1:Indolent NHL- toxicity, responses, engraftment

Toxicity

	N = 4
CRS Any grade ≥ Grade 2	 3/4 0/4
Neurotoxicity (ICANS) Any grade	 0/4
≥ Grade 3 Neutropenia Day -6 Day 28	 0/4 0/4

Engraftment



Responses based on Lugano Criteria and IHC (CD20)

	N = 4
CMR	4/4
PR	0/4
SD	0/4
PD	0/4



Serial LN Biopsies, CD20 by IHC, Dr Teresa Marafioti, UCL

Autolus

AUTO1:
Conclusions

- Tolerable Safety Profile was observed:
  - Despite high disease burden and despite heavily pre-treated patient population on study
    - No Grade 3 CRS was observed
    - Only 3/20 patients developed Grade 3 ICANS (rapid resolution with steroids)

- Robust expansion and prolonged CAR persistence was observed

- Efficacy in adult r/r ALL:
  - MRD negative CR was achieved in 16/19 (84%) patients at 1 month
  - EFS at 6 and 12 months is 69% and 52% respectively, in all treated patients
  - Responses are durable and ongoing CRs observed beyond 24 months, supporting the development of AUTO1 as a stand-alone therapy

- Promising early activity and safety has been observed in indolent NHL

Global Phase Ib/II AUTO1 study in r/r ALL has started

Commercial Opportunity – Adult ALL

Brent Rice

Vice President, Chief Commercial Officer, US

No Approved CAR T Therapy for Adult ALL Patients

Transformative therapy needed to address high unmet need despite current SOC

- Combination chemotherapy enables 90% of adult ALL patients to experience CR, but only 30% to 40% will achieve long-term remission
- Median overall survival is < 1 year in r/r ALL
- Only redirected T cell therapy approved for adults generally is blinatumomab
- CAR T therapies are highly active, but no clear sense of durability without subsequent allograft
- Patients are generally more fragile, more co-morbidities, yet CAR T toxicities in this setting have been notable with high incidences of severe CRS and cases of fatal neurotoxicity
- Opportunity to conduct further clinical study for second line treatment label increasing addressable patient population

FDA granted AUTO1 orphan drug designation for ALL

Autolus

*SEER and EUCAN estimates (respectively) for US and EU epi

Key Features of a Successful Therapy for Adult ALL

	Adult ALL Challenge	Product Property	CAR T Feature
● (grey)	Fast proliferating disease	Very high level of anti-leukemic activity	Rapid CAR T mediated kill and high level of CAR T expansion
● (green)	Almost stem cell like nature of leukemic cells	Sustain long term pressure on leukemia	Long CAR T persistence
● (purple)	Poor patient condition	Good tolerability	Minimize high grade CRS and NT

AUTO1 Holds Promise for Patients as Potential Standalone Therapy

A cross study comparison of AUTO1 vs Standard of Care

	[1]AUTO1	Standard of Care	
	All patients	[2]Blinatumumab	[3]Inotuzumab
Patient Numbers	19	271	218
CR Rate	84%	44%	80.7%
EFS 6m	69%	31%	mPFS 5m
(EFS 12m)	*(52%)*		
CRS ≥ Grade 3†	0%	3%	0%
Neurotox ≥ Grade 3†	15%*	13%	0%
Other notable toxicities			14% Hepatic VoD

†20 patients evaluable for safety

- Approximately 50% of blinatumumab and inotuzumab patients received subsequent HSCT
- Veno-Occlusive Disease (VoD) during treatment and following subsequent HSCT, with the latter causing a higher post-HSCT non-relapse mortality rate, has limited inotuzumab uptake

* Observed in patients with > 50% tumor burden
1. Roddie et al., ASH 2020
2. Kantarjian et al., 2017
3. Kantarjian et al., 2016

Autolus

Adult ALL is a Promising Commercial Opportunity with Limited Competition

R/R adult ALL is three times the size of r/r pediatric ALL



Additional potential for AUTO1 to move to 1st and 2nd lines

Autolus

Source: DRG

Capitalizing on the Unique Profile of AUTO1 in Adult ALL

Exploration of AUTO1 activity in additional B-Cell malignancies

PRODUCT	INDICATION	TARGET	Phase 1	Pivotal
AUTO1	Adult ALL	CD19	ALLCAR19	AUTO1-AL1
AUTO1	iNHL & CLL	CD19	ALLCAR19 ext.	
AUTO1	Primary CNS Lymphoma*	CD19	CAROUSEL	
AUTO1/22	Pediatric ALL	CD19 & CD22	CARPALL ext.	

*Primary CNS lymphoma annual incidence approx. 1400 cases in the US . Reference: Keva Green; Jeffery P. Hogg https://www.ncbi.nlm.nih.gov/books/NBK545145/.

Autolus

AUTO1 is Designed for Potential Best-In-Class Efficacy and Safety

Novel construct for durable responses without allo-transplant and absence of severe CRS

- Novel CD19 CAR designed for use as a stand-alone curative therapy
- Potential transformative clinical profile with high rates of durable complete responses
- Highly differentiated clinical profile with potential for hospital outpatient treatment in Academic and Non-Academic Transplant Centers
- Differentiated product profile should open access to larger market opportunity, potential to reduce burden on healthcare resources and patients
- Opportunity to pursue in earlier lines of therapy and indications outside of adult ALL

Summary and Next Steps

Dr. Christian Itin

Chairman and CEO

Summary of AUTO1 and AUTO3 Clinical Programs

- AUTO1
  - High level of sustained CRs, durability of remissions highly encouraging
  - Well tolerated, despite high disease burden and heavy pre-treatment of the patients in this study
  - Currently enrolling Autolus' first Ph1b / 2 pivotal program with data planned in 2022
  - Adult ALL is an attractive commercial opportunity; initial target population is 3,000 patients in last line alone
  - ALLCAR study extension in iNHL and CLL ongoing
  - Opportunity to develop AUTO1 in Primary CNS Lymphoma, study start planned for Q1 2021
- AUTO3
  - AUTO3 continues to show a differentiated product profile supporting possible out-patient administration
  - Complete response rates are consistently high across all dose levels, data point to a potential to further improve on clinical outcome
  - Assessing a development strategy that potentially optimizes the development path in r/r DLBCL
  - Plan to update on next steps in Q1 2021

Multiple Clinical Milestones Planned Through Q4 2020 / 2021

PRODUCT	INDICATION	TARGET	EVENT
AUTO1	Adult ALL	CD19	Ph1 long-term follow up, AL-1 data in 2022
AUTO1/22	Pediatric ALL	CD19 & CD22	Started Ph1 Q4 2020
AUTO1	PCNSL	CD19	Ph1 study start Q1 2021
AUTO3	DLBCL	CD19 & CD22	Ph1 long-term follow up, update on next steps
AUTO4	TRBC1+ Peripheral TCL	TRBC1	Ph1 interim data 2021
AUTO6NG	Neuroblastoma; Melanoma; Osteosarcoma; SCLC	GD2	Start Ph1 2021
AUTO7	Prostate Cancer	PSMA	Start Ph1 H1 2022
AUTO8	Multiple Myeloma	BCMA & CAR X	Start Ph1 study H1 2021
Allo Product	Undisclosed	Undisclosed	Start Ph1 H1 2021

Autolus B Cell Malignancies T Cell Lymphoma Solid Tumors Multiple Myeloma Allogeneic Approach

Q&A

Dr. Christian Itin (Chairman and CEO)

Dr. Martin Pule (Founder and CSO)

Andrew Oakley (CFO)

Dr. Nushmia Khokhar (SVP, Head of Clinical Development)

Dr. Robert Chen (Executive Director, AUTO3 Program)

Brent Rice (VP, Chief Commercial Officer, US)

Thank you